About BioAtla, Inc.
https://www.bioatla.comBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
CEO
Jay M. Short
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citizens Capital Markets
Market Outperform
JMP Securities
Market Perform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:4.84M
Value:$1.64M
VANGUARD GROUP INC
Shares:1.95M
Value:$659.62K
TANG CAPITAL MANAGEMENT LLC
Shares:1.37M
Value:$465.81K
Summary
Showing Top 3 of 50
About BioAtla, Inc.
https://www.bioatla.comBioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $13.73M ▼ | $-15.78M ▲ | 0% | $-0.27 ▲ | $-15.72M ▲ |
| Q2-2025 | $0 | $18.08M ▲ | $-18.71M ▼ | 0% | $-0.32 ▼ | $-18.53M ▼ |
| Q1-2025 | $0 | $17.43M ▲ | $-15.33M ▼ | 0% | $-0.26 ▲ | $-17.43M ▼ |
| Q4-2024 | $0 ▼ | $4.59M ▼ | $-14.88M ▼ | 0% ▲ | $-0.3 ▼ | $-16.02M ▼ |
| Q3-2024 | $11M | $22.04M | $-10.59M | -96.24% | $-0.22 | $-11.04M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $8.32M ▼ | $15.91M ▼ | $47.15M ▲ | $-31.24M ▼ |
| Q2-2025 | $18.21M ▼ | $27.13M ▼ | $43.87M ▲ | $-16.75M ▼ |
| Q1-2025 | $32.36M ▼ | $38.29M ▼ | $37.74M ▼ | $547K ▼ |
| Q4-2024 | $49.05M ▼ | $52.42M ▼ | $38.16M ▼ | $14.27M ▼ |
| Q3-2024 | $56.52M | $62.24M | $39.27M | $22.97M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-15.78M ▲ | $-9.88M ▲ | $0 | $-6K ▼ | $-9.89M ▲ | $-9.88M ▼ |
| Q2-2025 | $-18.71M ▼ | $-14.2M ▲ | $0 | $42K ▲ | $-14.16M ▲ | $0 ▲ |
| Q1-2025 | $-15.33M ▼ | $-16.29M ▲ | $0 | $-395K ▼ | $-16.68M ▼ | $-16.29M ▲ |
| Q4-2024 | $-14.88M ▼ | $-16.78M ▼ | $0 | $9.31M ▲ | $-7.47M ▼ | $-16.78M ▼ |
| Q3-2024 | $-10.59M | $-5.13M | $0 | $-14K | $-5.15M | $-5.13M |
CEO
Jay M. Short
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 19
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Citizens Capital Markets
Market Outperform
JMP Securities
Market Perform
HC Wainwright & Co.
Neutral
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ACORN CAPITAL ADVISORS, LLC
Shares:4.84M
Value:$1.64M
VANGUARD GROUP INC
Shares:1.95M
Value:$659.62K
TANG CAPITAL MANAGEMENT LLC
Shares:1.37M
Value:$465.81K
Summary
Showing Top 3 of 50